Fox Chase Cancer Center
Fox Chase Cancer Center was one of the nation's first comprehensive cancer centers, designated by the National Cancer Institute in 1974. Fox Chase's activities include basic, clinical and prevention research; detection and treatment of cancer; and community outreach programs.
Fox Chase was formed in 1974 by the union of American Oncologic Hospital (the nation's first cancer hospital, established in 1904) and the Institute for Cancer Research (founded in 1927). Today it has almost 2,500 employees and an operating budget of $319 million for fiscal year 2008. Research is conducted in more than 80 laboratories by a staff of more than 350 physicians and scientists who hold medical degrees, Ph.D.s or both.
Fox Chase's 100-bed hospital is one of the few facilities in the country devoted entirely to cancer care. Annual hospital admissions average about 4,600 and outpatient visits to physicians exceed 77,000 a year. In September 2000, the Hospital of Fox Chase Cancer Center became the nation's first comprehensive cancer center and Pennsylvania's first hospital to receive Magnet status for nursing excellence from the American Nurses Credentialing Center, which renewed this honor in 2004 and again in 2009, making it the first institution in Pennsylvania to be re-designated twice and one of the few in the country.
In 2010, Fox Chase opened the Women's Cancer Center, a place where women can receive coordinated, state-of-the-art care, support services, and education all under one roof.
About 215 clinical trials of new prevention, diagnostic and treatment techniques are under way at any one time. Almost 620 new patients a year participate in treatment studies. Fox Chase is also involved in developing trials to test new agents that may prevent cancer in high-risk individuals and is an active participant in the national trials to prevent breast cancer and prostate cancer. Combining research in many disciplines with patient care enables Fox Chase to translate new research findings into medical applications that may become models for improved cancer care.
The interdisciplinary approach to cancer research at Fox Chase offers opportunities not found in single discipline or department settings, fostering an interactive atmosphere that is the hallmark of research at Fox Chase. Current faculty research programs are wide-ranging and include Cancer Biology, Cancer Prevention and Control, Immune Cell and Host Defense, Molecular Translational Medicine, and Women's Cancers. In addition to these research programs, Fox Chase created The Keystone Programs for Collaborative Discovery, a suite of innovative team-based cancer research initiatives, which launched in February 2008.
Our goals are not only to provide outstanding care but also to improve the diagnosis and treatment of cancer - and eventually to prevent it. The Research Institute for Cancer Prevention, the first comprehensive program of its kind in the nation, was dedicated in 2000 in the Prevention Pavilion on the Fox Chase campus. The five-story Pavilion provides 120,000 square feet of space for both research and clinical programs dedicated to eradicating the many diseases called cancer.
Among the prevention-related services offered are special programs to help people with family histories or other specific risks of breast and ovarian cancer, gastrointestinal cancers, melanoma and prostate cancer. The Prevention Pavilion also includes new laboratories devoted to prevention-oriented research. The expanded radiation therapy facility is located on the ground floor of the Pavilion.
In 1986, Fox Chase established partnerships with community hospitals in the region. Fox Chase Partners now includes 24 hospitals in Pennsylvania and New Jersey. This program has been successful in raising the quality of cancer care in the community and increasing the number of patients enrolled in clinical trials. In 1995, Fox Chase also became a founding member of the National Comprehensive Cancer Network, (NCCN), a not-for-profit alliance of 21 of the world's leading cancer centers, dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Fox Chase investigators have received numerous awards and honors, including Nobel Prizes in medicine and chemistry; the Kyoto Prize; a Lasker Clinical Research Award; memberships in the National Academy of Sciences; General Motors Cancer Research Foundation Prizes; American Cancer Society Medals of Honor; and induction into the National Inventors Hall of Fame.
Media inquiries only, please contact Diana Quattrone at 215-728-7784.